Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-09
2007-01-09
Flood, Michele (Department: 1655)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S751000
Reexamination Certificate
active
10147389
ABSTRACT:
The invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.
REFERENCES:
patent: 4725609 (1988-02-01), Kull, Jr. et al.
patent: 5318957 (1994-06-01), Cid et al.
patent: 5508030 (1996-04-01), Bierman
patent: 5547965 (1996-08-01), Kr uger et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5866561 (1999-02-01), Ungs
patent: 5869037 (1999-02-01), Crystal et al.
patent: 6417205 (2002-07-01), Cooke et al.
patent: 409219 (2005-06-01), None
patent: 3645036 (1989-01-01), None
patent: WO 97/34605 (1997-09-01), None
patent: WO 99/35131 (1999-07-01), None
patent: WO 00/23062 (2000-04-01), None
Belluardo, et al. (1998). “Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat”,Neuroscience, 83(3): 723-740.
Bornmyr, et al. (1991) “Thermography and laser—Doppler flowmetry for monitoring changes in finger skin blood upon cigarette smoking”,Clinical Physiology, vol. 11: 135-141.
Carty, et al. (1996). “Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells”,J. of Vascular Surgery, vol. 24(6): 927-934.
Damaj, et al. (1998). “Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice”,J. of Pharmacology and Experimental Therapeutics, vol. 284(3): 1058-1065.
Decker, et al. (1999) “Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics”,Biochem. Pharm., vol. 58: 917-923.
Folkman, et al. (1996). “Blood vessel formation: What is its molecular basis?”,Cell, vol. 87: 1153-1155.
Grando, et al. (1995) “A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes”,J. Invest. Dermatol., vol. 105: 774-781.
Grando, et al. (1996) “Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation”,J. Invest. Dermatol., vol. 107: 412-418.
Grando, et al. (2000) “Nicotine and Pemphigus”,Arch Dermatol, 136:1269.
Haas, et al. (1992) “Jean Nicot 1530-1600”,J. Neurol Neurosurg. Psychiatry, vol. 55: 430.
Hanahan et al. (1996) “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis”,Cell, vol. 86: 353-364.
Kanekura, et al. “Successful treatment of pyoderma gangrenosum with nicotine chewing gum”,Letters to the Editor, pp. 704-705.
Kanekura, et al. (1995) “Nicotine for pyoderma gangrenosum”,Lancet345:1058.
Lopez- Arrieta et al. (2000), “Nicotine for Alzheimer's disease”,Cochrane Database Syst Rev, (2)CD001749.
Macklin, et al. (1998). “Human vascular endothelial cells express functional nicotinic acetylcholine receptors”,J. of Pharmacology and Experimental Therapeutics, vol. 287: 435-439.
Moffett, et al, (1998). “Increased tyrosine phosphorylation and novelcis-acting element mediate activastion of the fibroblast growth factor-2 (FGF-2) gene by nicotinic acetylcholine receptor, New mechanism for trans-synaptic regulation of cellular development and plasticity”,Molecular Brain Res., vol. 55: 293-305.
Møller, et al. (2002) “Effect of preoperative smoking intervention on postoperative complications: A randomized clinical trial”,Lancet, vol. 359: 144-177.
Pullan, et al (1994) “Transdermal nicotine for active ulcerative colitis”,New England Journal of Medicine, vol. 330: 811-815.
Sandborn (1999). “Nicotine therapy for ulcerative colitis: A review of rationale, mechanisms, pharmacology, and clinical results”,American J. of Gastroenterology, vol. 94(5): 1161-1171.
Schneid, et al. “Nicotine patches for aphthous ulcers due to Behcet's syndrome”,New England Journal of Medicine, 2000343:1816-1817.
Tonnesen, et al. (1991) “A double-blind trial of a 16-hour transdermal nicotine patche in smoking cessation”,New England Journal of Medicine, 325:311-315.
Usuki, et al. (1998) “Effects of nicotine on peripheral cutaneous blood flow and skin temperature”,J. Dermatol. Sci., vol. 16: 173-181.
Vieregge, et al. “Transdermal nicotine in PD: a randomized, double-blind, placebo controlled study”,Neurology2001, 57:1032-1035.
Villablanca (1998). “Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro”,American Physiological Society, pp. 2089-2098.
Volm, et al. (1999). “Angiogenesis and cigarette smoking in squamous cell lung carcinomas: an Immunohistochemical study of 28 cases”,Anticancer Research, vol. 19: 333-336.
Westerman, et al. (1993) “The role of skin nociceptive afferent nerves in blister healing”,Clinical and Experimental Neurology, vol. 30; 39-60.
Yancopoulos, et al. (1998). “Vasculogenesis, angiogenesis, and growth factors: Ephrins enter the fray at the border”Cell, vol. 93: 661-664.
Heeschen, Christopher et al., “Nicotine is an agent of angiogenesis: Role of nitric oxide and prostacyclin” Journal of American College Cardiology, vol. 35, No. 2, Suppl. A, Feb. 2000, pp. 545A-546A XP001180280, 29thAnnual Scientific Session of the American College of Cardiology, Anaheim, CA, USA Mar. 12-15, 2000, ISSN: 0735-1097.
Cooke John
Heescheen Christopher
Jang James
Tsao Phillip
Borden Paula A.
Bozicevic Field & Francis LLP
Flood Michele
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Nicotine in therapeutic angiogenesis and vasculogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nicotine in therapeutic angiogenesis and vasculogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotine in therapeutic angiogenesis and vasculogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807983